CAJ | 학술논문

目的：探讨细胞因子诱导的杀伤（cytokine induced killer，CIK）细胞联合FOLFOX4方案化疗治疗晚期结肠癌的临床疗效。方法将85例晚期结肠癌患者进行随机分组：治疗组43例，给予FOLFOX4方案化疗+CIK细胞治疗；对照组42例，给予FOLFOX4方案化疗。比较两组患者的免疫功能、生活质量、近期疗效、远期生存率及不良反应。结果经过治疗后，治疗组CD3+、CD4+、CD4+/CD8+比值及CD16+CD56+显著上升，CD8+细胞显著下降，与治疗前相比差异有统计学意义（P＜0.05）；对照组CD3+、CD4+、CD8+、CD4+/CD8+及CD16+CD56+与治疗前相比差异无统计学意义（P＞0.05）。治疗组QOL评分改善83.7%，明显高于对照组的33.3%（P＜0.001）。治疗组客观有效率为67.4%，对照组为61.9%，两组比较差异无统计学意义（P=0.593）。治疗组和对照组的1年、2年生存率分别为93.0%vs 83.3%，81.4%vs 69.0%，两组比较差异无统计学意义（P=0.166，P=0.187）。治疗组和对照组的不良反应无显著差异（P＞0.05）。结论 CIK细胞联合化疗可以提高晚期结肠癌患者的免疫功能，改善生活质量。
목적：탐토세포인자유도적살상（cytokine induced killer，CIK）세포연합FOLFOX4방안화료치료만기결장암적림상료효。방법장85례만기결장암환자진행수궤분조：치료조43례，급여FOLFOX4방안화료+CIK세포치료；대조조42례，급여FOLFOX4방안화료。비교량조환자적면역공능、생활질량、근기료효、원기생존솔급불량반응。결과경과치료후，치료조CD3+、CD4+、CD4+/CD8+비치급CD16+CD56+현저상승，CD8+세포현저하강，여치료전상비차이유통계학의의（P＜0.05）；대조조CD3+、CD4+、CD8+、CD4+/CD8+급CD16+CD56+여치료전상비차이무통계학의의（P＞0.05）。치료조QOL평분개선83.7%，명현고우대조조적33.3%（P＜0.001）。치료조객관유효솔위67.4%，대조조위61.9%，량조비교차이무통계학의의（P=0.593）。치료조화대조조적1년、2년생존솔분별위93.0%vs 83.3%，81.4%vs 69.0%，량조비교차이무통계학의의（P=0.166，P=0.187）。치료조화대조조적불량반응무현저차이（P＞0.05）。결론 CIK세포연합화료가이제고만기결장암환자적면역공능，개선생활질량。
Objective To observe the clinical efficacy of cytokine-induced killer cells (CIK) combined with FOLFOX4 regimen chemotherapy for advanced colorectal cancer. Method A total of 85 patients with advanced colorectal cancer were randomized into treatment group or control group. In treatment group, 43 patients received FOLFOX4 chemotherapy + CIK cell therapy; while in control group, 42 patients were administered with FOLFOX4 chemotherapy. The immune function, quality of life, short-term effect, long-term survival and adverse reactions of the two groups were analyzed. Result After treatment, the levels of CD3+, CD4+, CD4+/CD8+ ratio and CD16 + CD56 + were increased and the CD8+ was decreased significantly (P< 0.05) in the treatment group, and those measures in the control group showed no significant changes (P> 0.05). Quality of life of 83.7% patients in the treatment group was improved, which was significantly higher than the 33.3% in the control group (P< 0.001). The objective re-sponse rates (ORR) in treatment group and control group were 67.4% vs 61.9%, of which the difference was not sig-nificant (P= 0.593). The 1-year and 2-year survival rate in treatment group and control group were 93.0% vs 83.3%, 81.4% vs 69.0%, and there were no statistically significant differences between two groups (P= 0.166, P= 0.187). Al-so, the side effects in the both groups were similar (P> 0.05). Conclusion CIK cells combined with chemotherapy in the treament of advanced colorectal cancer can improve patients' immune function and quality of life.